Transcatheter pulmonary valve replacement (TPVR) has transitioned from an experimental technique to a standard of care over the last 10 years, with its application expanding from conduit-based right ventricular outflow tracts (RVOTs) to complex native or patch-repaired anatomies. Valve systems like Melody, Sapien, and Harmony have shown favorable safety and efficacy, achieving a 10-year freedom from reintervention of 60% (95%CI 55%-65%) and freedom from valve dysfunction of 53% (95%CI 47%-59%). For severely dilated RVOTs, innovations like the Alterra adaptive stent and physician-modified endografts offer new solutions. Patient selection is now a comprehensive process, evaluating RV function, coronary compression risk, and anatomy. Standardized perioperative management has markedly lowered major complication rates. Advanced technologies such as 3D printing, finite element analysis, and virtual reality are paving the way for precision medicine in TPVR. For pediatric patients, prospective technologies like growable valves and fetal interventions represent new frontiers. With maturing technology and broadening indications, TPVR is progressively extending to younger patients, underscoring the importance of multidisciplinary teams and long-term follow-up for safety. This review systematically outlines the technological evolution, current status, and future trajectory of TPVR.